Alnylam Pharmaceuticals Inc
XETRA:DUL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Alnylam Pharmaceuticals Inc
XETRA:DUL
|
US |
|
Lithium Americas Corp
TSX:LAC
|
CA |
|
A
|
ASM International NV
OTC:ASMIY
|
NL |
|
Symrise AG
F:SY1U
|
DE |
|
Stora Enso Oyj
OTC:SEOAY
|
FI |
|
S
|
Stantec Inc
F:S3A
|
CA |
|
A
|
ADT Inc
F:541
|
US |
|
Advantest Corp
OTC:ADTTF
|
JP |
|
Y
|
Yankuang Energy Group Co Ltd
SWB:YZCA
|
CN |
|
Q2 Metals Corp
F:458
|
CA |
|
Leone Film Group SpA
MIL:LFG
|
IT |
|
A
|
Air China Ltd
XMUN:AD2
|
CN |
|
V
|
Vienna Insurance Group AG Wiener Versicherung Gruppe
XBER:WSV2
|
AT |
|
R
|
Refrigeration Electrical Engineering Corp
VN:REE
|
VN |
|
Atoss Software AG
XETRA:AOF
|
DE |
|
S
|
Schlumberger NV
XHAM:SCL
|
US |
|
Medinova Diagnostic Services Ltd
BSE:526301
|
IN |
|
C
|
China Citic Bank Corp Ltd
XBER:D7C
|
CN |
|
Sto SE & Co KgaA
F:STO3
|
DE |
|
OC Oerlikon Corporation AG Pfaeffikon
F:OBH
|
CH |
|
Cipher Pharmaceuticals Inc
TSX:CPH
|
CA |
|
F
|
FirstGroup PLC
XBER:FGR
|
UK |
|
B
|
Bajaj Finance Ltd
BSE:500034
|
IN |
|
I
|
ITM Power PLC
OTC:ITMPF
|
UK |
Wall St Price Targets
DUL Price Targets Summary
Alnylam Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for DUL is 381.27 EUR with a low forecast of 199.85 EUR and a high forecast of 498.28 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is DUL's stock price target?
Price Target
381.27
EUR
According to Wall Street analysts, the average 1-year price target for DUL is 381.27 EUR with a low forecast of 199.85 EUR and a high forecast of 498.28 EUR.
What is the Revenue forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
17%
Over the last 13 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 8 years is 17%.
What is the Operating Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
36%
The compound annual growth rate for Operating Income over the next 8 years is 36%.
What is the Net Income forecast for Alnylam Pharmaceuticals Inc?
Projected CAGR
41%
The compound annual growth rate for Net Income over the next 8 years is 41%.
